Where Will Exact Sciences Be in 5 Years?
Exact Sciences (NASDAQ: EXAS) emerged as a leading developer of cancer diagnostics following the successful development and launch of Cologuard, its non-invasive test for colorectal cancer. While the initial adoption of Cologuard continues to grow, Exact continues to broaden its product offerings.
Cancer diagnostic companies seek to capitalize on new technologies for earlier detection and the ever-growing shift toward personalized medicine. Early detection using a non-invasive approach, like a simple blood test, can potentially save lives by starting intervention sooner.
Image source: Getty Images.
Source Fool.com
